Ocuphire Pharma Investor Presentation Deck

APX3330 VEGF Effects in Normal Cells APX3330 Restores Normal Levels Unlike Biologic Anti-VEGFs that Reduce VEGF Below Normal Normal Conditions: Physiological level of VEGF activity Abnormal Conditions (e.g., hypoxic): Ocuphire Increased level of VEGF activity PHARMA Biologic anti-VEGF agents inactivate VEGF directly and reduce VEGF levels below normal levels Biologic Anti-VEGF Treatment Kamba 2007; Girardi 2010; Li 2014 APX3330 Investigator Brochure APX3330 Anti-Ref-1 Treatment Inhibition of Ref-1 by APX3330 returns VEGF levels to normal levels APX3330 prevents VEGF overproduction in ARPE-19 cells VEGF Concentrations (% of Control) 500 450 400 350 300 250 200 150 100 50 0 OXLDL APX3330 ARPE-19 cell line + * VEGF is a growth factor that is necessary for normal function of multiple cell types including vascular endothelium and neurons → By returning VEGF levels to normal, APX3330 can reduce neovascularization, vascular leakage and the inflammatory response without adverse systemic effects p<0.05 The safety profile of APX3330 to date has not shown any of the adverse effects that has been seen with systemic administration of anti-VEGF biologics such as cardiovascular pathology, hypertension, arteriothrombotic events, or renal dysfunction + 150μg/mL + 30μM 18

View entire presentation